Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,256,534 papers from all fields of science
Search
Sign In
Create Free Account
cisplatin/pentoxifylline
Known as:
CDDP/PTX
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Cisplatin
Pentoxifylline
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Combined Delivery and Anti-Cancer Activity of Paclitaxel and Curcumin Using Polymeric Micelles.
Xiang Gao
,
Bilan Wang
,
+7 authors
C. Gong
Journal of Biomedical Nanotechnology
2015
Corpus ID: 25654880
Paclitaxel (PTX) is efficacious in treating various solid tumors. However, the severe adverse effects of its present formulation…
Expand
2012
2012
Electron Paramagnetic Resonance Highlights That the Oxygen Effect Contributes to the Radiosensitizing Effect of Paclitaxel
F. Danhier
,
P. Danhier
,
+6 authors
V. Préat
PLoS ONE
2012
Corpus ID: 5761477
Background Paclitaxel (PTX) is a potent anti-cancer chemotherapeutic agent and is widely used in the treatments of solid tumors…
Expand
2012
2012
Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion
I. Kretzer
,
D. Maria
,
R. C. Maranhão
Cellular Oncology
2012
Corpus ID: 256110077
Lipid nanoemulsions (LDE) may be used as carriers of paclitaxel (PTX) and etoposide (ETP) to decrease toxicity and increase the…
Expand
2011
2011
Effect of Trajectory Design on Susceptibility Compensation of Whole Brain Parallel Transmission for UHF fMRI
Hai Zheng
,
T. Zhao
,
Y. Qian
,
T. Ibrahim
,
F. Boada
2011
Corpus ID: 47014740
Introduction: Ultra high field (UHF) MRI has been used to render superior anatomy previously unattainable at lower field. However…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE